EPH receptors in cancer

Histology and Histopathology

Volumn 23, Issue 8, 2008, Pages 1011-1023

  Castaño, Julio ^a,b   Davalos, Veronica ^a,b   Schwartz Jr, Simo ^a,b   Arango, Diego ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cancer; EPH receptors; Ephrins; Tumorigenesis

Indexed keywords

ANIMALIA;

EPHRIN; EPHRIN RECEPTOR; TUMOR MARKER;

CELL MOTION; CELL SHAPE; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; HUMAN; MALE; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CELL MOVEMENT; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPHRINS; FEMALE; HUMANS; MALE; NEOPLASMS; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 46249124604     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Alazzouzi H., Davalos V., Kokko A., Domingo E., Woerner S.M., Wilson A.J., Konrad L., Laiho P., Espin E., Armengol M., Imai K., Yamamoto H., Mariadason J. M., Gebert J.F., Aaltonen L.A., Schwartz S., Jr. and Arango D. (2005). Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res. 65, 10170-10173.
2. Banyard J., Anand-Apte B., Symons M. and Zetter B.R. (2000). Motility and invasion are differentially modulated by Rho family GTPases. Oncogene 19, 580-591.
3. Batlle E., Bacani J., Begthel H., Jonkheer S., Gregorieff A., van de Born M., Malats N., Sancho E., Boon E., Pawson T., Gallinger S., Pals S. and Clevers H. (2005). EphB receptor activity suppresses colorectal cancer progression. Nature 435, 1126-1130.
4. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., Meeldijk J., Robertson J., van de Wetering M., Pawson T. and Clevers H. (2002). Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111, 251-263.
5. Berclaz G., Karamitopoulou E., Mazzucchelli L., Rohrbach V., Dreher E., Ziemiecki A. and Andres A.C. (2003). Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann. Oncol. 14, 220-226.
6. Brantley-Sieders D., Schmidt S., Parker M. and Chen J. (2004a). Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr. Pharm. Des. 10, 3431-3442.
7. Brantley-Sieders D.M., Caughron J., Hicks D., Pozzi A., Ruiz J.C. and Chen J. (2004b). EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell. Sci. 117, 2037-2049.
8. Brantley D.M., Cheng N., Thompson E.J., Lin Q., Brekken R.A., Thorpe P.E., Muraoka R.S., Cerretti D.P., Pozzi A., Jackson D., Lin C. and Chen J. (2002). Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011-7026.
9. Bruckner K., Pablo Labrador J., Scheiffele P., Herb A., Seeburg P.H. and Klein R. (1999). EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron 22, 511-524.
10. Bruckner K., Pasquale E.B. and Klein R. (1997). Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275, 1640-1643.
11. Carles-Kinch K., Kilpatrick K.E., Stewart J.C. and Kinch M.S. (2002). Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 62, 2840-2847.
12. Chaib H., Cockrell E.K., Rubin M.A. and Macoska J.A. (2001). Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 3, 43-52.
13. Cheng N., Brantley D. M., Liu H., Lin Q., Enriquez M., Gale N., Yancopoulos G., Cerretti D.P., Daniel T.O. and Chen J. (2002). Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 1, 2-11.
14. Cheng N., Brantley D., Fang W.B., Liu H., Fanslow W., Cerretti D.P., Bussell K.N., Reith A., Jackson D. and Chen J. (2003). Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5, 445-456.
15. Chiari R., Hames G., Stroobant V., Texier C., Maillère B., Boon T. and Coulie P.G. (2000). Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 60, 4855-4863.
16. Chong L.D., Park E.K., Latimer E., Friesel R. and Daar I.O. (2000). Fibroblast growth factor receptor-mediated rescue of x-ephrin B1- induced cell dissociation in Xenopus embryos. Mol. Cell Biol. 20, 724-734.
17. Clarke A R. (2006). Wnt signalling in the mouse intestine. Oncogene 25, 7512-7521.
18. Clevers H. and Batlle E. (2006). EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res. 66, 2-5.
19. Cortina C., Palomo-Ponce S., Iglesias M., Fernández-Masip J.L., Vivancos A., Whissell G., Humà M., Peiró N., Gallego L., Jonkheer S., Davy A., Lloreta J., Sancho E. and Batlle E. (2007). EphBephrin- B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat. Genet. 39, 1376-1383.
20. Croft D.R., Sahai E., Mavria G., Li S., Tsai J., Lee W.M., Marshall C.J. and Olson M.F. (2004). Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res. 64, 8994-9001.
21. Davalos V., Dopeso H., Castano J., Wilson A.J., Vilardell F., Romero-Gimenez J., Espin E., Armengol M., Capella G., Mariadason J.M., Aaltonen L.A., Schwartz S., Jr. and Arango D. (2006). EPHB4 and survival of colorectal cancer patients. Cancer Res. 66, 8943-8948.
22. Davalos V., Dopeso H., Velho S., Ferreira A.M., Cirnes L., Diaz-Chico N., Bilbao C., Ramirez R., Rodriguez G., Falcon O., Leon L., Niessen R.C., Keller G., Dallenbach-Hellweg G., Espin E., Armengol M., Plaja A., Perucho M., Imai K., Yamamoto H., Gebert J.F., Diaz- Chico J.C., Hofstra R.M., Woerner S.M., Seruca R., Schwartz S., Jr. and Arango D. (2007). High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 26, 308-311.
23. Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V., Pawson T., Goldfarb M. and Yancopoulos G. D. (1994). Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266, 816-819.
24. Davy A. and Robbins S.M. (2000). Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. EMBO J. 19, 5396-5405.
25. Davy A., Gale N.W., Murray E.W., Klinghoffer R.A., Soriano P., Feuerstein C. and Robbins S.M. (1999). Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 13, 3125-3135.
26. Dobrzanski P., Hunter K., Jones-Bolin S., Chang H., Robinson C., Pritchard S., Zhao H. and Ruggeri B. (2004). Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 64, 910-919.
27. Dohn M., Jiang J. and Chen X. (2001). Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503-6515.
28. Dottori M., Down M., Hüttmann A., Fitzpatrick D.R. and Boyd A.W. (1999). Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94, 2477-2486.
29. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W. and Whang E.E. (2004). EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23, 1448-1456.
30. Easty D.J. and Bennett D.C. (2000). Protein tyrosine kinases in malignant melanoma. Melanoma Res. 10, 401-411.
31. Easty D.J., Hill S.P., Hsu M.Y., Fallowfield M.E., Florenes V.A., Herlyn M. and Bennett D.C. (1999). Up-regulation of ephrin-A1 during melanoma progression. Int. J. Cancer 84, 494-501.
32. Ellis C., Kasmi F., Ganju P., Walls E., Panayotou G. and Reith A.D. (1996). A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Oncogene 12, 1727-1736.
33. Ellis S. and Mellor H. (2000). Regulation of endocytic traffic by rho family GTPases. Trends Cell Biol. 10, 85-88.
34. Folkman J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
35. Fox B.P. and Kandpal R.P. (2004). Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem. Biophys. Res. Commun. 318, 882-892.
36. Fox B.P. and Kandpal R.P. (2006). Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem. Biophys. Res. Commun. 340, 268-276.
37. Fox B.P., Tabone C.J. and Kandpal R.P. (2006). Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem. Biophys. Res. Commun. 342, 1263-1272.
38. Guo D.L., Zhang J., Yuen S.T., Tsui W.Y., Chan A.S., Ho C., Ji J., Leung S.Y. and Chen X. (2006). Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27, 454-464.
39. Hafner C., Bataille F., Meyer S., Becker B., Roesch A., Landthaler M. and Vogt T. (2003). Loss of EphB6 expression in metastatic melanoma. Int. J. Oncol. 23, 1553-1559.
40. Hafner C., Schmitz G., Meyer S., Bataille F., Hau P., Langmann T., Dietmaier W., Landthaler M. and Vogt T. (2004). Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50, 490-499.
41. Hafner C., Becker B., Landthaler M. and Vogt T. (2006). Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod. Pathol. 19, 1369-1377.
42. Heath J.P. (1996). Epithelial cell migration in the intestine. Cell Biol. Int. 20, 139-146.
43. Henkemeyer M., Orioli D., Henderson J.T., Saxton T.M., Roder J., Pawson T. and Klein R. (1996). Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Cell 86, 35-46.
44. Herath N.I., Spanevello M.D., Sabesan S., Newton T., Cummings M., Duffy S., Lincoln D., Boyle G., Parsons P.G. and Boyd A.W. (2006). Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6, 144.
45. Himanen J.P. and Nikolov D.B. (2003). Eph signaling: a structural view. Trends Neurosci. 26, 46-51.
46. Hirai H., Maru Y., Hagiwara K., Nishida J. and Takaku F. (1987). A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238, 1717-1720.
47. Hock B., Bohme B., Karn T., Feller S., Rubsamen-Waigmann H. and Strebhardt K. (1998). Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions. Oncogene 17, 255-260.
48. Holland S.J., Gale N.W., Gish G.D., Roth R.A., Songyang Z., Cantley L.C., Henkemeyer M., Yancopoulos G.D. and Pawson T. (1997). Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J. 16, 3877-3888.
49. Holland S.J., Gale N.W., Mbamalu G., Yancopoulos G.D., Henkemeyer M. and Pawson T. (1996). Bidirectional signalling through the EPHfamily receptor Nuk and its transmembrane ligands. Nature 383, 722-725.
50. Holmberg J., Genander M., Halford M.M., Annerén C., Sondell M., Chumley M.J., Silvany R.E., Henkemeyer M. and Frisén J. (2006). EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 125, 1151-1163.
51. Huynh-Do U., Stein E., Lane A.A., Liu H., Cerretti D.P. and Daniel T.O. (1999). Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 18, 2165-2173.
52. Iiizumi M., Hosokawa M., Takehara A., Chung S., Nakamura T., Katagiri T., Eguchi H., Ohigashi H., Ishikawa O., Nakamura Y. and Nakagawa H. (2006). EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci. 97, 1211-1216.
53. Ikegaki N., Tang X.X., Liu X.G., Biegel J.A., Allen C., Yoshioka A., Sulman E.P., Brodeur G.M. and Pleasure D.E. (1995). Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum. Mol. Genet. 4, 2033-2045.
54. Kalo M.S. and Pasquale E. B. (1999). Signal transfer by Eph receptors. Cell Tissue Res. 298, 1-9.
55. Kataoka H., Igarashi H., Kanamori M., Ihara M., Wang J.D., Wang Y.J., Li Z.Y., Shimamura T., Kobayashi T., Maruyama K., Nakamura T., Arai H., Kajimura M., Hanai H., Tanaka M. and Sugimura H. (2004). Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 95, 136-141.
56. Kinch M.S., Moore M.B. and Harpole D.H. Jr (2003). Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 9, 613-618.
57. Kullander K. and Klein R. (2002). Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3, 475-486.
58. Kumar S.R., Singh J., Xia G., Krasnoperov V., Hassanieh L., Ley E. J., Scehnet J., Kumar N.G., Hawes D., Press M.F., Weaver F.A. and Gill P.S. (2006). Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am. J. Pathol. 169, 279-293.
59. Labrador J.P., Brambilla R. and Klein R. (1997). The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling. EMBO J. 16, 3889-3897.
60. Lackmann M., Oates A.C., Dottori M., Smith F.M., Do C., Power M., Kravets L. and Boyd A.W. (1998). Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J. Biol. Chem. 273, 20228-20237.
61. Lai K.O., Chen Y., Po H.M., Lok K.C., Gong K. and Ip N.Y. (2004). Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression. J. Biol. Chem. 279, 13383-13392.
62. Laiho P., Kokko A., Vanharanta S., Salovaara R., Sammalkorpi H., Jarvinen H., Mecklin J.P., Karttunen T.J., Tuppurainen K., Davalos V., Schwartz S. Jr., Arango D., Makinen M.J. and Aaltonen L.A. (2007). Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26, 312-320.
63. Lin H.S., Berry G.J., Fee W.E. Jr, Terris D.J. and Sun Z. (2004). Identification of tyrosine kinases overexpressed in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 130, 311-316.
64. Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan F., Bucana C.D. and Ellis LM. (2002). Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94, 934-939.
65. Lugli A., Spichtin H., Maurer R., Mirlacher M., Kiefer J., Huusko P., Azorsa D., Terracciano L., Sauter G., Kallioniemi O.P., Mousses S. and Tornillo L. (2005). EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin. Cancer Res. 11, 6450-6458.
66. Martiny-Baron G., Korff T., Schaffner F., Esser N., Eggstein S., Marme D. and Augustin H.G. (2004). Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6, 248-257.
67. Maru Y., Hirai H. and Takaku F. (1990). Overexpression confers an oncogenic potential upon the eph gene. Oncogene 5, 445-447.
68. Maru Y., Hirai H., Yoshida M.C. and Takaku F. (1988). Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol. Cell. Biol. 8, 3770-3776.
69. Masood R., Kumar S.R., Sinha U.K., Crowe D.L., Krasnoperov V., Reddy R.K., Zozulya S., Singh J., Xia G., Broek D., Schonthal A. H. and Gill P.S. (2006). EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int. J. Cancer 119, 1236-1248.
70. Miao H., Burnett E., Kinch M., Simon E. and Wang B. (2000). Activation of EphA2 kinase suppresses integrin function and causes focaladhesion- kinase dephosphorylation. Nat. Cell Biol. 2, 62-69.
71. Miao H., Wei B.R., Peehl D.M., Li Q., Alexandrou T., Schelling J.R., Rhim J.S., Sedor J.R., Burnett E. and Wang B. (2001). Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 3, 527-530.
72. Miyazaki T., Kato H., Fukuchi M., Nakajima M. and Kuwano H. (2003). EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer 103, 657-663.
73. Mizejewski G.J. (1999). Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 222, 124-138.
74. Murai K.K. and Pasquale E.B. (2003). 'Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 116, 2823-2832.
75. Nakada M., Niska J.A., Miyamori H., McDonough W.S., Wu J., Sato H. and Berens M.E. (2004). The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 64, 3179-3185.
76. Nakamura R., Kataoka H., Sato N., Kanamori M., Ihara M., Igarashi H., Ravshanov S., Wang Y.J., Li Z.Y., Shimamura T., Kobayashi T., Konno H., Shinmura K., Tanaka M. and Sugimura H. (2005). EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 96, 42-47.
77. Noren N.K. and Pasquale E.B. (2004). Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal. 16, 655-666.
78. Ogawa K., Pasqualini R., Lindberg R.A., Kain R., Freeman A.L. and Pasquale E.B. (2000). The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043-6052.
79. Orsulic S. and Kemler R. (2000). Expression of Eph receptors andephrins is differentially regulated by E-cadherin. J. Cell Sci. 113 (Pt 10), 1793-1802.
80. Palmer A., Zimmer M., Erdmann K.S., Eulenburg V., Porthin A., Heumann R., Deutsch U. and Klein R. (2002). EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell. 9, 725-737.
81. Pandey A., Lazar D.F., Saltiel A.R. and Dixit V.M. (1994). Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J. Biol. Chem. 269, 30154-30157.
82. Pasquale E.B. (2005). Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6, 462-475.
83. Pawson T. (2002). Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (Suppl 5), S3-10.
84. Reya T. and Clevers H. (2005). Wnt signalling in stem cells and cancer. Nature 434, 843-850.
85. Saito T., Masuda N., Miyazaki T., Kanoh K., Suzuki H., Shimura T., Asao T. and Kuwano H. (2004). Expression of EphA2 and Ecadherin in colorectal cancer: correlation with cancer metastasis. Oncol. Rep. 11, 605-611.
86. Shamah S. M., Lin M. Z., Goldberg J. L., Estrach S., Sahin M., Hu L., Bazalakova M., Neve R. L., Corfas G., Debant A. and Greenberg M. E. (2001). EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 105, 233-244.
87. Sinha U.K., Kundra A., Scalia P., Smith D. L., Parsa B., Masood R. and Gill P.S. (2003). Expression of EphB4 in head and neck squamous cell carcinoma. Ear. Nose. Throat J. 82, 866, 869-870, 887.
88. Sinha U.K., Mazhar K., Chinn S.B., Dhillon V.K., Liu L., Masood R., Rice D.H. and Gill P.S. (2006). The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 132, 1053-1059.
89. Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J., Chen K., Saul A., Nikolov D. and Boyd A.W. (2004). Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen. J. Biol. Chem. 279, 9522-9531.
90. Stein E., Cerretti D.P. and Daniel T.O. (1996). Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J. Biol. Chem. 271, 23588-23593.
91. Stein E., Huynh-Do U., Lane A.A., Cerretti D.P. and Daniel T.O. (1998). Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J. Biol. Chem. 273, 1303-1308.
92. Stephenson S.A., Slomka S., Douglas E.L., Hewett P.J. and Hardingham J.E. (2001). Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol. Biol. 2, 15.
93. Surawska H., Ma P.C. and Salgia R. (2004). The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 15, 419-433.
94. Takai N., Miyazaki T., Fujisawa K., Nasu K. and Miyakawa I. (2001). Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol. Rep. 8, 567-573.
95. Takasu M.A., Dalva M.B., Zigmond R.E. and Greenberg M.E. (2002). Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 295, 491-495.
96. Tang X.X., Evans A.E., Zhao H., Cnaan A., London W., Cohn S.L., Brodeur G.M. and Ikegaki N. (1999). High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin. Cancer Res. 5, 1491-1496.
97. Tang X.X., Zhao H., Robinson M.E., Cnaan A., London W., Cohn S.L., Cheung N.K., Brodeur G.M., Evans A.E. and Ikegaki N. (2000a). Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med. Pediatr. Oncol. 35, 656-658.
98. Tang X.X., Zhao H., Robinson M.E., Cohen B., Cnaan A., London W., Cohn S.L., Cheung N.K., Brodeur G.M., Evans A.E. and Ikegaki N. (2000b). Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc. Natl. Acad. Sci. USA 97, 10936-10941.
99. Tang X.X., Evans A.E., Zhao H., Cnaan A., Brodeur G.M. and Ikegaki N. (2001). Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med. Pediatr. Oncol. 36, 80-82.
100. Thaker P.H., Deavers M., Celestino J., Thornton A., Fletcher M. S., Landen C. N., Kinch M. S., Kiener P. A. and Sood A. K. (2004). EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 10, 5145-5150.
101. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., Tjon-Pon-Fong M., Moerer P., van den Born M., Soete G., Pals S., Eilers M., Medema R. and Clevers H. (2002). The betacatenin/ TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-50.
102. Walker-Daniels J., Coffman K., Azimi M., Rhim J.S., Bostwick D.G., Snyder P., Kerns B.J., Waters D.J. and Kinch M.S. (1999). Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41, 275-280.
103. Wang H.U., Chen Z.F. and Anderson D.J. (1998). Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753.
104. Wang J., Kataoka H., Suzuki M., Sato N., Nakamura R., Tao H., Maruyama K., Isogaki J., Kanaoka S., Ihara M., Tanaka M., Kanamori M., Nakamura T., Shinmura K. and Sugimura H. (2005). Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24, 5637-5647.
105. Wu Q., Suo Z., Kristensen G.B., Baekelandt M. and Nesland J.M. (2006). The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol. Oncol. 102, 15-21.
106. Wu Q., Suo Z., Risberg B., Karlsson M.G., Villman K. and Nesland J.M. (2004). Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol. Oncol. Res. 10, 26-33.
107. Wykosky J., Gibo D.M., Stanton C. and Debinski W. (2005). EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541-551.
108. Xia G., Kumar S.R., Masood R., Koss M., Templeman C., Quinn D., Zhu S., Reddy R., Krasnoperov V. and Gill P.S. (2005a). Up-regulation of EphB4 in mesothelioma and its biological significance. Clin. Cancer Res. 11, 4305-4315.
109. Xia G., Kumar S. R., Masood R., Zhu S., Reddy R., Krasnoperov V., Quinn D. I., Henshall S.M., Sutherland R.L., Pinski J.K., Daneshmand S., Buscarini M., Stein J. P., Zhong C., Broek D., Roy-Burman P. and Gill P.S. (2005b). EphB4 expression and biological significance in prostate cancer. Cancer Res. 65, 4623-4632.
110. Xia G., Kumar S.R., Stein J.P., Singh J., Krasnoperov V., Zhu S., Hassanieh L., Smith D.L., Buscarini M., Broek D., Quinn D.I., Weaver F.A. and Gill P.S. (2006). EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25, 769-780.
111. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J. and Holash J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248.
112. Yang N.Y., Pasquale E.B., Owen L.B. and Ethell I.M. (2006). The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J. Biol. Chem. 281, 32574-32586.
113. Zantek N.D., Azimi M., Fedor-Chaiken M., Wang B., Brackenbury R. and Kinch M. S. (1999). E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 10, 629-638.
114. Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R. and Kinch M.S. (2001). EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 61, 2301-2306.
115. Zeng G., Hu Z., Kinch M.S., Pan C.X., Flockhart D.A., Kao C., Gardner T.A., Zhang S., Li L., Baldridge L.A., Koch M.O., Ulbright T.M., Eble J.N. and Cheng L. (2003). High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am. J. Pathol. 163, 2271-2276.
116. Zisch A.H., Kalo M.S., Chong L.D. and Pasquale E.B. (1998). Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region. Oncogene 16, 2657-2670.